Eli Lilly continues to dominate the GLP-1 market, while Pfizer struggles to grow sales. Their diverging positions are reflected in their valuations, with Eli Lilly’s stock soaring by nearly 200% since 2023, compared to Pfizer’s decline. Eli Lilly is investing in expanding manufacturing, while Pfizer focuses on acquisitions. Financially, Eli Lilly’s sales are expected to reach $63 billion this year with a 40% increase, while Pfizer anticipates revenue of $62 billion. Eli Lilly’s profit margins are around 31%, stronger than Pfizer’s 16%. In terms of valuation, Eli Lilly trades at a P/E of 52, much higher than Pfizer’s 15. Despite Eli Lilly’s growth, Pfizer may offer more value for investors with its lower valuation.

Read more at Nasdaq: Better Buy in 2026: Pfizer or Eli Lilly?